More than 25 antiretroviral drugs from six therapeutic classes are now available for the
management of HIV infection (box 1). Most patients who take medication achieve durable and …

Now that we are over 10 years into the HAART era in resource-rich countries the major clinical
impact of this therapy on reduced AIDS events and AIDS deaths has been well described […

This article aims to build a picture of HIV epidemiology in Europe by combining existing
surveillance data to mathematical modelling to achieve observations closer to the dynamic …

Background Randomised placebo-controlled trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However, …

Background With the advent of effective antiretroviral treatment, the life expectancy for
people with HIV is now approaching that seen in the general population. Consequently, the …

Background Insufficient data are available from single cohort studies to allow estimation of
the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral …

Background Data from randomized trials are lacking on the benefits and risks of initiating
antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) …

Background The introduction of combination antiretroviral therapy and protease inhibitors has
led to reports of falling mortality rates among people infected with HIV-1. We examined the …

Meta-analysis is a statistical procedure that integrates the results of several independent
studies considered to be “combinable.” 1 Well conducted meta-analyses allow a more objective …

Importance A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral
therapy (ART) as a prevention strategy is the absolute risk of HIV transmission through …